Q-omics provides the consensus-scored DNM1P35 profile across patient tissues and cancer cell-line models. DNM1P35 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, DNM1P35 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DNM1P35 RNA expression shows 15,600 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, HNSC, and TGCT as cancer lineages where DNM1P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM1P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM1P35 survival associations across molecular data types. DNM1P35 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM1P35 RNA expression–survival associations across cancer types. High DNM1P35 expression shows unfavorable associations in COAD, ACC, LGG and CHOL, but favorable associations in OV and BLCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for DNM1P35 RNA expression.
This table summarizes DNM1P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DNM1P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM1P35 shows lower tumor expression in UCEC and BRCA and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher DNM1P35 RNA expression in tumor versus normal tissue (log2 FC = +0.233, t-test p < 0.001).
This table shows molecular features associated with DNM1P35 in patient tissues and cancer cell lines. In patient samples, DNM1P35 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
